Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice

Thrombosis and Haemostasis

Volumn 104, Issue 2, 2010, Pages 252-260

  Delavenne, Xavier ^a,b   Zufferey, Paul ^a,b   Baylot, Denis ^c   Nguyen, Philippe ^d   Borg, Jeanne Yvonne ^e   Fontenay, Michaela ^f   Deygas, Beatrice ^b,g   Mismetti, Patrick ^a,b   Laporte, Silvy ^a,b,g  

^a University Jean Monnet of Saint Etienne EA3065   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c Clinique Mutualiste de Saint Etienne   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f Cochin Hospital ^*  (France)

^g INSERM   (France)

Author keywords

Fondaparinux; Orthopedic surgery; Pharmacokinetics; Simulations

Indexed keywords

BLOOD CLOTTING FACTOR 10A; FONDAPARINUX;

ADULT; AGE; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BODY WEIGHT; CLINICAL TRIAL; COHORT ANALYSIS; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BODY WEIGHT; COMPUTER SIMULATION; CREATININE; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; FRANCE; HEMORRHAGE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 77955439928     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-02-0127     Document Type: Article

References (25)

1. Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381-453.
2. Turpie A, Bauer K, Eriksson B, et al.; Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003; 90: 364-366.
3. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41: 1-9. (Pubitemid 35155551)
4. Turpie AG, Lensing AW, Fuji T, et al. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 2009; 20: 114-121.
5. Eriksson BI, Bauer KA, Lassen MR, et al. Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-1304.
6. Turpie AG, Gallus AS, Hoek JA. Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-625.
7. Turpie AG, Bauer KA, Eriksson BI, et al. PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-1726.
8. Rosencher N, Vielpeau C, Emmerich J, et al. ESCORTE group. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost 2005; 3: 2006-2014.
9. Samama CM, Ravaud P, Parent F, et al. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost 2007; 5: 2360-2367.
10. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008; 100: 453-461.
11. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572-585.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
13. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
14. Laroche L, Charmes JP, Marcheix A, et al. Estimation of glomerular filtration rate in the elderly: Cockcroft -Gault formula versus modification of diet in renal disease formula. Pharmacother 2006; 26: 1041-1046.
15. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999; 104: 230-240.
16. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982; 8: 195-222.
17. Sheiner LB, Grasela TH. An introduction to mixed effect modelling: concepts, definitions and justification. J Pharmacokinet Biopharm 1991; 19: 11-24.
18. Wählby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2001; 28: 231-252.
19. Jadhav PR, Gobburu JV. A new equivalence based metric for predictive check to qualify mixed-effects models. AAPS J 2005; 7: 523-523.
20. Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46: 221-234.
21. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-512.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: 1-266.
23. Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004; 38: 73-77.
24. Berges A, Laporte S, Epinat M , et al. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 2007; 64: 428-438.
25. Arixtra. Fondaparinux sodium. Summary of product characteristics. European Agency for the Evaluation of Medicinal Products (EMEA). Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/arixtra/011502en6.pdf. Accessed January 15, 2010.